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ABSTRACT 
 
Neurodegenerative diseases are extremely debilitating and affect a large portion 
of the population. Quality care for diseases such as multiple sclerosis relies heavily on 
the development of therapeutic agents by pharmaceutical companies. Currently neuronal 
drug development processes are time consuming and costly. This has led to a lack of 
commercially available drugs targeted at the nervous system. This thesis presents a novel 
neuronal cell microfluidic chip in response to this problem. In many neurodegenerative 
diseases, demyelination of the axons plays a critical role. This thesis presents a novel 
way to improve the efficiency of a neuronal cell aggregate device for myelination 
studies. The device is fabricated using traditional lithography techniques to pattern three 
inch SU-8 wafers. These wafers are then used as the master molds for the fabrication of 
polydimethylsiloxane (PDMS) devices. The device incorporates multiple normally 
closed micro valves. Fabrication of neuronal aggregate trapping structures is necessary 
and required the use of Inductively Coupled Plasma (ICP) to etch trenches in silicon. 
Neuronal aggregates are loaded into the device and trapped in a specific culturing 
chamber by pillar trapping structures. Unused aggregates are reflowed through the 
device until all the aggregate trapping sites are full. The aggregates are then cultured for 
multiple weeks. During culturing, myelin is produced by the aggregates. The goal of the 
device is to enhance drug testing related to the myelination of neurons and limit the need 
of animal models for such drug testing. This thesis focuses on the creation of a device 
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that is able to reflow the unused neuronal aggregates back through the trapping 
chambers.  
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CHAPTER I  
INTRODUCTION AND LITERATURE REVIEW 
 
1.1 Myelination and Demyelinating Diseases 
Over 2.3 million people are affected with multiple sclerosis worldwide according 
to the National Multiple Sclerosis Society. Many more are affected with dementias such 
as Alzheimer’s disease. What links these diseases is not only that they attack the 
neurological system, but that they result in the demyelination of neurons.  
Myelin is a fatty substance that surrounds neuronal axons. It is produced by 
Schwann cells in the peripheral nervous system and by oligodendrocyte cells in the 
central nervous system. The importance of myelin resides in the fact that it increases the 
speed of the electrical signal flowing along the axon. Myelin insulates the axon, 
improving the speed of signal transmission. More specifically, myelin ensures 
membrane depolarization occurs only at the nodes of Ranvier as shown in Figure 1.  
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Figure 1: Neuron cell 
 
Such controlled depolarization of the axons allows for signal propagation [6]. 
Without the myelin sheath in Figure 2, the transmission of the ion cascade along the 
axon is too slow for the brain to send or receive messages. This results in impaired motor 
control and degradation of neuronal pathways. A significant amount of research focuses 
on studying and understanding ways to prevent demyelination as well as repair damaged 
myelin.  
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Figure 2: Myelination of neurons with surrounding Schwann cells 
 
Much of this research focuses on discovering the mechanisms behind severely 
debilitating dementias such as Alzheimer’s disease. Alzheimer’s disease attacks the 
white matter of the brain (WM) resulting in lesion formation in the WM. Luxol fast blue 
(LFB) staining of myelin in the WM of those who suffered from dementing disorders 
showed significantly increased myelin loss in the frontal lobe [5]. Research into the 
mechanisms behind this myelin loss as well as the mechanisms behind myelin 
development are underway. Determining why some axons are myelinated and some are 
not is still unknown and highlights the need for increased research [6]. The thickness 
of myelin on the axon also plays an important role in proper functioning of the axon. 
Myelin thickness is typically measured using the g-ratio (axonal diameter/axonal 
diameter and myelin sheath). This ratio is usually the same for different axons in 
animals. Therefore, larger axons normally have a larger myelin sheath [6]. Discovering 
signaling molecules that affect the development and thickness of the myelin sheath is a 
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focal point of research. Currently, the ErbB3 receptor system is believed to affect the 
thickness of myelination of neurons [6]. Disruption of this receptor affects the 
Schwann cells surrounding the axon. Adjusting the ErbB3 receptor system may result 
in a possible therapy for dementias. Another possibly therapeutic treatment for 
Alzheimer’s and other demyelinating diseases are Rho kinases (ROCKS). Rho kinases 
were shown in 2005 to inhibit regeneration of neuronal tissue. Conversely, inhibition 
of ROCKS shows increased neuron regeneration in damaged tissue [10]. This includes 
regeneration of tissue damaged by diseases such as Alzheimer’s and other dementias. 
Developing inhibitors of ROCKS will increase the regeneration of damaged neural 
tissue. Despite the promising outlook for such a therapeutic, ROCKS inhibitors are still 
undergoing clinical trials with the FDA.  
Another disease that would be affected by inhibition of rho kinases is Multiple 
Sclerosis (MS). Signaling pathways play an important role in the onset of MS. MS 
affects the ability of axons to remyelinate. Fibroblast growth factor 9 (FGF9) has been 
shown to prevent myelination and remyelination of axons. Excessive amounts of FGF9 
indirectly affect oligodendrocyte cells. The mechanism has been linked to secretions 
by astrocyte cells surrounding the oligodendrocyte cells [7]. Inhibition of the FGF 
signaling pathway in astrocyte cells may serve as a therapeutic treatment that would 
increase remyelination of neurons in patients with MS [7]. Another potentially related 
therapy for MS is the regulation of the astrocyte response to increased immune 
activity. Astrocytes, one of the cells that support neurons, play a significant role in the 
demyelination of axons in patients with MS. During an increased immune response, 
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astrocytes breakdown the myelin sheath. MS is an autoimmune disease and results in 
an immune response against neuronal cells and the myelin surrounding the axons. 
Astrocytes contribute to the immune response by breaking down the myelin sheath [8]. 
Regulating the uptake of myelin by astrocytes may serve as a potential treatment for 
the slowing of demyelination as a result of MS [8].  
Despite such innovative research, current MS therapeutic treatments still rely 
on suppression of the immune system. New oral medications such as Fingolimod work 
by reducing the amount of white blood cells that enter the central nervous system 
(CNS) [9]. Such therapeutics only indirectly treat MS. A similar problem occurs for 
medications targeting various dementias. As previously mentioned, new potentially 
revolutionary drugs such as ROCKS inhibitors have yet to become commercially 
available. Current therapeutics available for the treatment of dementia only slow the 
disease. The lack of suitable commercially available drugs for neurodegenerative 
diseases is apparent and results from multiple factors.  
One of the factors is the increased cost and complexity of developing drugs 
targeted at the nervous system. Drugs targeted at the nervous system have a 95% rate of 
failure and take 10-15 years to move from conceptualization to commercialization [11]. 
A prime example is the number of drugs related to Alzheimer’s disease. The number of 
drug failures for Alzheimer’s disease has been estimated at 101 since 1998 as compared 
to 3 successes [11]. Such high failure rates affect the number of neurologically related 
drugs that pharmaceutical companies are willing to invest in. In a recent report published 
by Tufts University, a total amount of $2.6 billion was said to have been spent on 
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average to produce a new pharmaceutical drug [12]. The study was based on information 
obtained from 10 unnamed drug makers. Of the $2.6 billion, almost half or 
approximately $1.2 billion was ascribed to capital lost due to potential drug failure [12]. 
This amount is even higher for drugs targeted at the nervous system. The amount of time 
the drug companies spend researching a drug that fails is counted as a cost in the 
development of a new successful drug. The remaining $1.4 billion is spent on actual 
research for the drug [12]. Reducing the cost of research will reduce the cost of failure. 
Having a cost effective way to test possible neurological drug candidates will increase 
the efficiency and decrease the cost of drugs targeted at the nervous system.  
Traditionally, pharmaceutical companies are required to perform multiple in vivo 
animal studies before beginning clinical trials. These animal studies are necessary. 
However, they add greatly to the cost of drug production. The creation of a high 
throughput device that enables pharmaceutical companies to test different drug 
concentrations before initiating animal testing will greatly reduce the cost of drug 
development by limiting the number of animal trials. Having a cheaper alternative to 
animal testing will limit the cost of failure by providing prescreening of potential drug 
candidates. A high throughput screening platform for neurological drug candidates 
allows a large number of potential candidates to be tested in a relatively cheap manner. 
Only the drug candidates that are successful will move on to more expensive animal 
testing. The requirements for such a high throughput system are that it simulates the in 
vivo environment and is cost effective. While it is challenging to mimic the in vivo 
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environment and maintain a cost effective platform, modern microfluidics has led to 
such breakthroughs.   
1.2 Micro Devices for Neuron Cell Culture 
Microfluidic devices play a large role in the creation of suitable in vitro 
environments for cell culturing. In contrast to standard petri dish cultures, fluidic devices 
enable modification of the cellular environment from culturing cells on membranes, to 
generating 3D cell cultures within integrated microfluidic systems [2, 22, 24]. 
Microfluidics allow for precise handling of small amounts of fluid as well as laminar 
fluid flow due to the small fluid volumes [22]. Through the use of membrane valves, 
microfluidic designs are able to precisely regulate fluid within microchannels [22, 26]. 
Automation of membrane valves enable the production of large integrated microfluidic 
designs [22, 23].  
Two major types of microfluidic valves are normally open and normally closed 
valves. Normally open valve require pressure to be applied to close the valve. Normally 
closed valves require negative pressure to open the valve layer.  
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                                           Figure 3: Normally closed valve design 
                                        
                                         Figure 4: Normally open valve design 
 
Negative pressure is applied to the PDMS valve layer in the case of the normally closed 
valve shown in Figure 3. This results in the popping up of the top part of the PDMS 
channel layer, which opens the valve to flow. Positive pressure is applied in the case of 
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the normally open valve in Figure 4 which results in the pushing down of the top part of 
the microfluidic channel layer, closing the channel to flow. Using the basic operating 
principles of the above designs, microfluidic large scale integration (mLSI) is possible 
[27]. Microfluidic large scale integration is the incorporation of multiple microfluidic 
valves for the automation of biological and chemical processes [27]. Such large scale 
integration is crucial for the development of high throughput microfluidic devices. The 
development of the microfluidic valve is analogous to the development of the transistor 
in the semiconductor industry. Increasing the valve density per microfluidic chip as well 
as the response time of the valves are key areas of research [27]. Multiple types of valves 
including heat sensitive resistive valves have been developed [27]. Within this work, we 
will rely on the traditional microfluidic valve designs fabricated through soft lithography 
methods and depicted in the above figures. Specifically, normally closed valves 
following the operation shown above, have been fabricated.  
Due to their miniaturized design, fluidic devices also provide for high throughput 
screening and testing. Parallelization of different processes on a single device allows for 
increased throughput [22]. High throughput screening (HTS) is a term used to describe 
the pharmaceutical industry’s drug testing process [2]. Through automation, multiple 
drug candidates are tested and their viability is measured. This system endeavors to be a 
low cost way to screen multiple experimental drugs. Various Lab-on-a-Chip and Organ-
on-a-Chip devices are fabricated in an attempt to harness these desirable characteristics 
of microfluidic devices. 
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Lab-on-a-Chip and Organ-on-a-Chip microfluidic devices are used in the 
characterization and culture of many different types of cells. The versatility of the design 
process for microfluidic devices enables the creation of a tailored cellular environment 
[24]. Liver cell cultures were one of the first cells to be cultured on a microfluidic device 
[2]. The need to culture liver cells in an environment that mimicked in vivo conditions 
was necessary to provide better drug testing [2].  
 
 
Figure 5: Example of early organ-on-a-chip culturing device. [2] 
 
In the above Figure 5, a cellular culturing device was fabricated using traditional 
microfluidic techniques and cultured liver and lung cells. The liver and lung areas of the 
chip provided the culturing sites for the cells. The gas and fat areas provided for in vivo 
like stimuli to influence cell growth and adaptation.  
Cellular microsystems have grown from the original liver on chip devices to even 
more advanced microfluidic devices. Devices have been customized to each particular 
cell type to provide the best environment for cellular growth [24]. Numerous 
 11 
 
microfluidic devices have been tailored to the culturing of neuronal cells. Some of the 
earliest neuronal cell culturing systems include the use of biomarkers and cell guidance 
[1]. Microfluidic neuronal cell culture systems are used to study the cues relating to axon 
guidance. This is crucial for the study of brain development and function. One way of 
tracking the growth of axons is by immobilizing proteins on the channel surfaces of the 
device. Culturing of cells for neuronal devices is often done in a larger area off chip. The 
mature neuronal cells are then delivered to the chip [1, 25].  
In Hong Yang, a leading researcher in neuroengineering, has developed a 
microfluidic platform that provides electrical stimulation to growing axons. 
 
 
Figure 6: Microfluidic device for electrical stimulation of neuronal axons. [13]  
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The device in Figure 6 incorporates two separate culturing chambers connected by a 
series of thin channels. This two chamber design has previously been used for neuronal 
research by Jeong Won Park et al [17]. Building from his design, Jean Michel Peyrin et 
al adjusted the widths and shapes of the channels connecting the somatic and axonal cell 
culturing chambers [19]. Such a two chamber design became the fundamental neuronal 
cell culturing microfluidic design. Yiing C. Yap et al incorporated such a design to test 
the response of neuronal cells to axon injury [18]. The novelty of such a design lies in 
the ability to structurally separate the axons from the neuronal cell body. Regarding the 
above figure, primary dorsal root ganglion cells (DRGs) were plated in the somatic 
chamber and their axons grew through the microchannels into the axonal chamber. 
Separation of the cell bodies with the axons allowed for independent testing of the 
neuronal cell bodies and the axons. Electrical stimulation was applied across the 
microchannels with electrodes positioned in each of the culturing chambers. Due to the 
high impedance within the microchannels, only the neurons with axons protruding 
through the microchannels received electrical stimulation. Oligodendrocyte progenitor 
cells (OPCs) were cultured in the axonal chamber. Oligodendrocytes were added to 
produce myelin sheaths around the axons. Results found that electrical stimulation 
resulted in increased maturation of the OPCs and increased myelination of the axons 
[13]. Maturation of the OPCs led to oligodendrocyte production of myelin. Such a 
device will be used to study the separate functioning of the axons and the cell body and 
how they sometimes operate independently from each other [13].  
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A similar device was developed by Eun-Mi Hur in collaboration with In Hong 
Yang to study the effects of chemotherapy on neuronal cells. The microfluidic device 
followed a similar design as the device previously described. It contained two neuronal 
cell culturing chambers, one for the main cell body and one for the axonal cell body. 
Application of a chemotherapeutic agent to the axonal and neuronal culturing chambers 
showed an increased detrimental effect on the axons [14]. Such a microfluidic system is 
used to study axonal degeneration which may include demyelination in future studies 
[14]. This microfluidic chip design consisting of two compartmentalized culture 
chambers was further used to study the effects of regenerative axonal growth [15]. Using 
a similar design, the neuronal growth cone, at the tip of each axon, was modified. The 
microtubules that attach to the growth cone were altered and this changed the shape of 
the cytoskeleton [15]. Such alterations increased the regeneration of axons from 
previously damaged neuronal cells [15].  
One of the drawbacks of the previously mentioned devices is the ability to load 
the neuronal cells into the somatic culturing chamber. This issue was addressed through 
the design of a circular somatic cell culturing chamber [25].  
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Figure 7: Circular neuronal aggregate device design. [25]  
 
In Figure 7, the mature neuronal cells were loaded into the center chamber and axon 
formation occurred through the microchannels into the axon/glia compartment. 
Separation of the neuronal cell bodies from the corresponding axons was achieved as 
well as easy loading of the neuronal cells. Furthermore, oligodendrocyte cells (OLs) 
were successfully cultured in the axon/glia compartment [25]. These cells are primarily 
responsible for the formation of myelin sheaths around axons.   
 Application of an electrical stimulus to neuronal cells is useful for many reasons 
including the possibility of increased myelination [3]. The inclusion of a microelectrode 
array (MEA) into the design of a neuronal microfluidic chip poses many advantages for 
delivering electrical stimulus to neuronal cells. As shown in the paper by Fabrice Morin 
et al, a MEA was used to record the electrical signals from neuronal networks cultured 
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on a microfluidic platform [16]. Both commercially available MEAs and custom planar 
MEAs were incorporated into the microfluidic system. The custom planar MEAs, as 
shown in Figures 8 and 9, were fabricated on a glass substrate using standard 
microfabrication techniques.  
 
 
Figure 8: Custom planar MEA. [16] 
  
Gold was used as the material for the electrodes. An intermediate chrome layer was used 
to bond the gold layer to the glass substrate. A spin-on-glass (SOG) layer was patterned 
to cover the gold wiring while allowing openings for the electrodes to interact with the 
neuronal cell culture.  
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Figure 9: Added PDMS layer with microwells for neuronal cell culture. [16] 
 
A layer of PDMS fabricated from an SU-8 mold was bonded to the MEAs. The neuronal 
cells were seeded ono the PDMS substrate and cultured. Their electrical signals were 
recorded for several weeks. This research demonstrated the ability to culture neuronal 
cells for long periods in microfluidic channels while simultaneously recording electrical 
stimulation. Electrical stimulation in the form of a biphasic square wave lasting a total of 
10 ms was applied to the stimulating electrode. The response of the electrical response of 
the neuronal cells to the stimulation was measured [16].  
 The incorporation of electrical stimulation into neuronal cell cultures within a 
microfluidic platform opens a host of opportunities for insight into neuronal cell function 
as well as various drug testing. Attaching the previous microelectrode array to the 
PDMS substrate proved challenging [16]. To avoid this problem, a microfluidic platform 
containing liquid electrodes was utilized and is depicted in Figure 10 [20]. Gallium and 
eutectic gallium were chosen as the liquid metals for the electrodes. A PDMS device was 
fabricated using SU-8 patterned silicon wafers and plasma bonded to a glass slide.  
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Figure 10: Electrical stimulation of neuronal cells. [20] 
 
Two channels were patterned for the electrodes in the PDMS. These channels were filled 
with the liquid metal and used as the electrodes. A positive and negative voltage was 
applied to each of the liquid electrode channels. Hippocampal neurons were harvested 
from E17 rats for culture in the microchannels [20].   
 The biocompatibility of the liquid metal electrodes was assessed by comparing 
neuronal cell proliferation close to the electrodes (less than 3mm) to proliferation further 
away (greater than 3mm). The cell viability close to the electrodes was similar to the 
cellular viability in other parts of the chip [20]. Calcium indicator dye provided a visual 
indication of neuronal cell stimulation. The hippocampal neurons exhibited 
depolarization in response to electrical stimulation of 0.6 mA by the metal liquid 
electrodes. Successful stimulation of the neurons using the metal electrodes eliminates 
the costly fabrication of MEAs and the bonding process with the PDMS channel layer 
[20]. Furthermore, gallium is known for its low toxicity as a metal and is often used in 
glass thermometers in replace of mercury. Despite these promising attributes, current 
microfluidic designs have revolved around conventional electrodes. This is most likely 
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due to the difficulties of working with a liquid metal including the ability to attach wires 
to a liquid. 
 In addition to microfluidic designs, an organic transistor was developed for 
electrically stimulating neurons [21]. The motivation behind producing an organic field 
effect transistor (OFET) include the drawbacks to using traditional MEAs to measure 
neuronal activity. MEAs suffer from attachment issues between the electrodes and the 
cells. Furthermore, the electrode impedance of an MEA limits its size and measurement 
sensitivity. The OFET proposed by Valentina Benfenat et al, has increased 
biocompatibility for long term cellular recordings and provides bidirectional electrical 
stimulation of neurons. Bidirectional stimulation should increase the functionality and 
response of neurons to electrical stimuli. The results of the OFET were compared to 
electrical stimulation of neurons by MEAs. The OFET was found to have a higher signal 
to noise ratio than the MEA. Dorsal root ganglion (DRG) primary neuron cells were 
cultured for the experiment [21].  
 
 
Figure 11: Organic Field Effect Transistor (OFET). [21]  
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The device in Figure 11 was manufactured using N,N0 - ditridecylperylene-3,4,9,10-
tetracarboxylic diimide (P13) as the organic semiconductor layer. The intracellular 
membrane potential of the neuronal cells was determined through traditional patch 
clamp techniques. When a current was initiated between the source and drain regions, 
the intracellular potential was monitored to ensure electrical stimulation of the neurons 
[21]. Device characterization was carried out to ensure the transistor was working 
properly. Current saturation graphs were obtained for different drain and source 
voltages. Once the set up mimicked transistor properties, experimental tests were 
conducted to vary the electrical stimulation across the neuronal layer by varying the 
source to drain current [21]. While not explicitly a microfluidic device, the above design 
seeks to achieve electrical stimulation of neurons for the purpose of biological study as 
well as eventual pharmaceutical applications. Moving from a device as previously 
presented to a practical device for drug testing has drawbacks both in terms of size and 
relative complexity. Two major advantages of microfluidic designs continue to be the 
decreased size and lower cost.  
 The previously discussed electrical stimulation of neurons proves important in 
the study of neuron myelination. The development of a drug screening device to test 
drugs that affect the myelination of neurons requires the formation of neuron aggregates. 
In vitro cultured individual neurons don’t produce myelin. Only groups of aggregated 
neurons form myelin sheaths. Therefore, in order to test the effects drugs have on myelin 
production, the first step is to form neuron aggregates. Neuron aggregates are formed in 
multiple ways. One way to form aggregates is to place individual neuron cells into a 
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poly dimethylenesiloxane (PDMS) tray with multiple microwells. The neuron cells 
attach to the surface of the tray and clump together in the micro wells. After a period of 
culturing, the clumps of neuron cells are removed from the microwells as aggregates.   
These aggregates are then transferred to the neuronal aggregate microfluidic 
device. Once loaded onto the device, the aggregates are flown through multiple culturing 
chambers. Aggregate trapping structures will be implemented into these chambers to 
capture the neuronal aggregates. Various cell trapping techniques were considered for 
the trapping of the neuronal aggregates. The typical aggregate size varied from 150-200 
um diameter spherical aggregates. Hydrodynamic traps as shown in the paper by Di 
Carlo follow the idea of allowing fluid flow through the trapping structure [28]. This is 
an important aspect of the neuronal aggregate trapping structure because the fluid flow 
through the trap leads to the trapping of the aggregate. Di Carlos employs hydrodynamic 
trapping to trap single HeLa cells, 20 um diameter, which are smaller in diameter than 
the aggregates [28]. Due to the size of the neuronal aggregates hydrodynamic trapping is 
not possible. Numerous other trapping techniques including dielectrophoresis (DEP) and 
magnetic trapping have been conducted within microfluidic devices [29]. DEP relies on 
generating a non-uniform electric field. Dielectric objects in the electric field experience 
a force that is used to move the objects into a trapping structure. These trapping 
techniques are effective however they increase the complexity of the system. For the 
longer term neuronal aggregate culture, a more practical aggregate trap exists [3].  The 
planned trapping structure for the aggregates is the previously fabricated three pillar 
design.  
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Figure 12: Previous microfluidic aggregate trapping design. [3] 
 
Figure 12 shows the previous microfluidic device and trapping structures that 
were previously tested to study the myelination of neuronal aggregates. The goal of this 
thesis is to improve the throughput of the above design and minimize the aggregate 
losses during loading. Previously, the aggregates were pipetted into the center of the 
above design. They flowed into all four of the surrounding trapping chambers. A very 
high aggregate concentration was used during the loading step due to high aggregate 
loss. Furthermore, not all of the aggregate traps in each trapping chamber were filled 
upon loading of the aggregates. Empty trapping sites reduced the efficacy of the device. 
This thesis addresses the above issues by providing a recirculation of initially un-trapped 
aggregates.  
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In addition to providing a recirculation design, similar pillar trapping designs 
were investigated and preliminary fabrication work was done. In the previous device, the 
aggregates were cultured for a period of up to four weeks in order for myelination to 
occur. Once myelination is quantified in the aggregates, drug compounds can be tested 
on the aggregates. The difficulties with such a system include the manual process of 
loading and unloading neuronal aggregates once they are formed. Another inherent 
difficulty is the trapping of neuronal aggregates within culturing sites after unloading 
from a microwell. Automation of a complete neuron aggregate formation and culturing 
system is necessary for introduction of such a system into the pharmaceutical industry. 
The following proposal introduces steps to achieve a high throughput neuronal aggregate 
trapping and culturing device. The goals of the device are to increase the throughput of 
the previous neuron aggregate culturing device as well as reduce neuronal aggregate 
loss. To improve neuronal aggregate loss, the design focuses on the recirculation of 
neuronal aggregates within a microfluidic device.  
 
 
 
 
 
 
 
 
CHAPTER II 
NEURONAL AGGREGATE DEVICE 
2.1 Design and Working Principle 
 A microfluidic device was fabricated to minimize neuronal aggregate loss for the 
previously mentioned myelination experiment. The device incorporates multiple 
microfluidic valves to reflow aggregates through the trapping chambers. Design 
constraints include the need to flow 200 um aggregates through the device. This 
necessitated designing the smallest channel to be at least 200 um height and 400 um 
width. Three input areas were incorporated into the device to prevent sticking of the 
aggregates along the edges of the channel during loading and for better control of the 
flow during cell loading. The recirculation of the free aggregates is performed through a 
series of steps. Each step involves the opening and closing of different microfluidic 
valves. The neuronal aggregates are first loaded into an initial reservoir chamber with an 
outlet channel. Once all the aggregates have been loaded into the initial reservoir 
chamber, the outlet chamber in the initial reservoir closes by action of a microfluidic 
valve. Next, a valve in the trapping chambers opens and the aggregates flow through the 
trapping chambers. The aggregates flow through the trapping chambers into the 
secondary reservoir. Once the aggregates move into the secondary reservoir, another 
microfluidic valve is opened and they flow back into the first reservoir where the process 
repeats until all trapping structures have been filled.     
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Figure 13: Reflow design 
 Currently, the design in Figure 13 incorporates three trapping chambers with 
no trapping structures. After proving reflow of the neuronal aggregates, the design 
will be fabricated to include the aggregate traps. The design will be expanded to 
include more trapping chambers.  
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Figure 14: Step 1 is the loading process of the aggregates 
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Figure 15: Step 2 is the aggregate trapping process 
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Figure 16: Step 3 is the reflow of remaining aggregates through the trapping structures 
The reflow of the neuronal aggregates depicted in Figures 14-16 recirculates the un-
trapped aggregates. This allows filling of any unfilled aggregate traps and minimizes the 
loss of previously un-trapped aggregates. 
2.2 Trapping Structures 
In addition to the above microfluidic design, the previously designed trapping 
structure was analyzed. The trap design was tested using COMSOL simulations and 
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fabrication was attempted using DRIE. The previously designed structure consisted of 
three pillars spaced approximately 35 um apart. The aspect ratio of these pillars 
approached 6. This proved difficult to fabricate using traditional SU-8 techniques. 
Therefore, fabrication was attempted using DRIE. Multiple potentially viable trapping 
structures were designed as alternatives to the previous trapping structure to potentially 
improve the fabrication process. The goal was to reduce the difficulty of the fabrication 
process for the neuronal aggregate traps. The size of the traps as well as the shape of the 
traps was altered in an attempt to accommodate the fabrication process.  
 
 
Figure 17: Microfabricated trapping pillars [3] 
 
 Comsol simulations were run for each of the trapping structures, including those 
shown in Figure 17, to measure the flow velocity around each of the trapping structures. 
A higher flow velocity is depicted in red and provides the most likely path for fluid to 
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flow. The traps were design to have high flow through the center of the trapping 
structures to increase the likelihood of trapping an aggregate. In the previous trapping 
structure a higher flow rate between the two trapping pillars allowed for fluid to flow 
into the trapping region. This high flow rate between the pillars of the trapping structure, 
seen in Figures 18 and 19, was mimicked in the new designs.  
 
 
Figure 18: Comsol simulation of previous aggregate trapping design. 
Figure 19: Comsol simulation of new block trapping structure. 
 The block pillar structures increased the size of the aggregate trap width by 
approximately 35 percent from 37 um to 50 um. Also, the length of the traps increased to 
approximately double. The space between the adjacent pillars was set at 50 um. A larger 
gap may allow the aggregates to pass though the two pillars. The distance between the 
two large pillars is 200 um, the size of the aggregates. Increasing the size of the structure 
as well as the gap should increase the ease of fabrication. A simulation combining 
multiple trapping structures is shown in Figure 20.  
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Figure 20: Comsol simulation of previous trapping structure. 
2.3 Fabrication of Neuronal Aggregate Device 
 SU-8 photoresist was patterned on 3’’ inch silicon wafers to form the molds for 
the PDMS channel and valve layers. The SU-8 was spin coated onto the wafers at 1000 
rpm for 1 min to obtain 200 um thickness. Next, the spin coated wafers were soft baked 
at 65C for over 24 hours. The wafers were hard baked at 95C for 40 minutes prior to UV 
exposure. The Karl Suss MA6 mask aligner in Aggiefab was used to expose the hard 
baked wafers to UV light. An intensity of 300mJ/cm2 was obtained to properly pattern 
the wafers. Post exposure baking was performed at 95C for 20 minutes. The wafers were 
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then developed using SU-8 developer for approximately 15 minutes. After developing 
the patterned wafers were rinsed using first IPA then DI water. Following developing, 
the wafers were air dried with nitrogen and coated with trichlorosilane. Evaporation of 
the trichlorosilane onto the wafers was performed in a vacuum chamber for 20 minutes. 
Once coated with trichlorosilane, the molds were ready for curing with PDMS.  
 Silicon elastomer 184 was the base PDMS polymer. It was mixed in a 10:1 ratio 
with curing agent to form the PDMS pre polymer. After thorough mixing, the mixture of 
base polymer and curing agent was degassed in a vacuum chamber. This degassing 
formed the PDMS pre polymer. The pre polymer was poured onto the SU-8 molds. To 
harden the PDMS, the degassed mixture was placed in a drying oven for over 40 
minutes. Once hardened, the cured PDMS could be cut out from the SU-8 molds. The 
cut out PDMS contained valve channels corresponding to the areas of hardened SU-8 
photoresist on the wafer. An overview of the fabrication procedure is shown in Figure 21.  
Figure 21: Fabrication process using SU-8 photoresist 
 To obtain the channel layer, a slightly different approach was employed. The 
channel layer needs to be thin for the valves to work properly. In order to obtain a thin 
channel layer, PDMS pre polymer was spin coated onto the SU-8 channel mold at 300 
rpm for 40 seconds. This obtained the proper thickness of 300 um. The spin coated 
wafer needs to be cured for at least 6-8 hours before removing the thin membrane. 
Attempting to remove the membrane without sufficient curing time led to distortion of 
features in the channel layer.  
 After curing of the channel and valve layers, they were removed from the SU-8 
molds. The top of the channel layer was bonded to the valve layer. The bonding process 
involved plasma treating the top channel layer and the bottom of the valve layer. The 
plasma treatment results in oxygen bonding to the surface of the PDMS. The oxygen 
saturated surfaces of the top of the channel layer and the bottom of the valve layer bond 
to each other. Aligning the channel layer with the valve layer required use of a special 
bonding technique following plasma treatment. Immediately following plasma 
treatment, the valve layer was placed on a hotplate at 150C. The valve layer was sprayed 
with methanol to prevent the channel layer from immediately bonding to the valve layer. 
This allowed for time to align the two layers. The methanol begin to evaporate 
immediately at a high temperature only allowing for a short time period for alignment. 
The bonding need to occur within 4 minutes for a good bond to occur between the two 
PDMS layers. After spraying the valve layer with methanol, the plasma treated side of 
the channel layer is aligned with the valve layer. Once alignment is finished, the 
remaining methanol evaporates and the two PDMS layers come into contact resulting in 
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bonding. The recently bonded PDMS layers are placed in a curing oven at 85C for 24 
hours. Baking in a curing oven removes remaining hydrophilicity in the channel layers 
preventing sticking of the channel to the valve layer in the next step. 
Figure 22: Fabrication of recirculation device 
 After 24 hours in a curing oven, the next plasma bonding step is introduced and 
is depicted in Figure 22. The bonded valve and channel layers are plasma treated along 
with a glass slide. Immediately following plasma treatment, the valves are actuated using 
10 mL syringes. This applies negative pressure to the valve layer and suck the channel 
wall below the valves up, essentially opening the channel. Sucking the channel layer 
below the valves up prevents it from sticking to the glass slide. After all the valves are 
actuated, the channel layer is bonded to the plasma treated side of the glass slide. It is 
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allowed to bond for at least 15 minutes. Time is given for the hydrophilicity of the glass 
to reduce so that the glass does not bond to the channel layer when the valves are closed. 
2.4 Fabrication of Trapping Structures 
 Initially, the fabrication of the trapping structures was performed using 
traditional SU-8 techniques as previously described. SU-8 was spin coated onto silicon 
wafers and exposed to UV light to form a master mold. Following SU-8 fabrication, 
Inductively Coupled Reactive Ion Etching (ICP-RIE) was used to etch silicon. 
 ICP-RIE was performed using Oxford Plasmalab 100 ICP-RIE system in 
Aggiefab. A 2000A layer of chrome was deposited on the surface of the silicon wafer 
and spin coated with photoresist. Following soft bake, the photoresist was patterned 
using UV light and developed. After developing, shown in Figure 23, the wafer was 
hard baked at 80 C for 10 minutes. 
Figure 23: After developing step 
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The wafer was then etched in chrome etchant as shown in Figure 24. The photoresist 
was then removed using a wash of first Isopropyl alcohol and then acetone. Any 
remaining photoresist was removed with cotton swabs soaked in acetone. The final step 
result is shown in Figure 25. 
 
 
Figure 24: After chrome etch 
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Figure 25: After PR strip.  
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CHAPTER III 
RESULTS AND DISCUSSION 
 
3.1 Recirculation Device Characterization  
 Polystyrene beads with 175 um diameter were flown through the recirculation 
device to test correct valve operation. The beads were successfully circulated throughout 
the device. They were loaded into reservoir 1 and flown through the aggregate trapping 
chambers. After loading into reservoir 2, they were recirculated back into reservoir 1. 
The process was repeated and the beads were successfully recirculated throughout the 
device. Some issues with polystyrene beads include sticking of the beads to PDMS 
substrate. This resulted in some of the beads sticking to the PDMS channel. In order to 
avoid this issue, a very high flow rate was used. Manual loading of the beads with a 
syringe required a much higher flow rate than with traditional cell aggregates.  
 After verification of the design concept with polystyrene beads, actual cell 
aggregates were loaded onto the microfluidic device. A HeLa cell line was used in the 
formation of the cell aggregates. This was done in lieu of neuronal aggregate cells due to 
the lack of neuronal cells. HeLa cells form good aggregates and are relatively easy to 
culture. The cell aggregates were formed by seeding the cell aggregates onto PDMS 
microwells. The cells were cultured on these microwells for up to one week to form tight 
aggregates. The aggregates were removed from the microwells and flown through the 
PDMS device. The loading of the aggregates was performed at a much slower flow rate 
than the polystyrene beads. The aggregates were flown into the device at a rate ranging 
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from 300 – 800 ul/min. This lower flow rate preserved the structure of the aggregates by 
preventing them from breaking apart. The size of the aggregates varied widely from 50 
to 150 um size. This non uniform size was due primarily to the lack of culture time in the 
microwells. In following experiments, the aggregates will be cultured for a period of two 
weeks or until tight spheroid formation is seen in the microwells. Furthermore, a low 
concentration of aggregates was used due to the lack of large aggregates of the size 150 
um or greater. Despite these drawbacks, basic functioning of the device was shown and 
the aggregates were circulated through the device. In future work, uniform cell 
aggregates will be cultured to further test the capabilities of the design. Different cell 
aggregates including both neuronal cells and HeLa cells will be cultured.  
3.2 Aggregate Trap Fabrication  
 The fabrication of the pillar structures using SU-8 was unsuccessful due to 
peeling of SU-8 from the master mold during removal of the PDMS. This resulted from 
the high aspect ratio of the pillar structures shown in Figure 27. In addition to the peeling 
of the SU-8, the resulting pillars were connected as shown in Figures 26 and 28. This 
prevented flow between the pillars. Removal of the chrome from the silicon was an issue 
as depicted in Figure 29.  
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Figure 26: SU-8 pillar structure exposed at 270 mJ/cm^2 UV intensity 
 
 
 
 
Figure 27: Sideview of pillar structure 
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Figure 28: 3D plot of etched trapping structure.  
 
 
 
 
Figure 29: Chrome mask removed from etched silicon wafer.   
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Figure 30: Depth profile of block structure.  
 
Previously a master mold for the aggregate traps was fabricated in a DRIE in 
Korea. This was due to the high aspect ratio of the pillars. The attempts to increase the 
size and reduce the aspect ratio of the trapping structures were a step towards successful 
fabrication. Further etching tests need to be performed to determine the maximum 
distance needed to correctly resolve two aggregate trapping pillars.  
 An etching depth of up to 150 um was achieved and is shown in Figure 30. This 
is sufficient for an aggregate size of 150 – 200um. However, the sidewall passivation 
resulted in merging of the pillar structures and further research into the proper distance 
between etched structures is required. Altering the ratio of SF6 gas to O2 should change 
the sidewall characteristics of the etch. Increasing the amount of O2 should increase 
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sidewall passivation thus resulting in a straighter sidewall. The downside to increased O2 
passivation is the reduced silicon etch rate. A faster etch rate is important when 
considering the depth of the etch is 200 um. Various ratios of SF6 to O2 were attempted 
and compared in Table 1.  
 
  SF6 O2 RF Power ICP 
Power 
Chamber 
Pressure 
Temp 
 Oxford 
Recipe 
70 sccm 4.5 sccm 5W 900W 10 mTorr -100 C 
Song Recipe  70 sccm 20 sccm 20W 900W 10 mTorr -100 C 
Previous 
Recipe (Akil 
45 min etch) 
90 sccm 30 sccm 10W 900W 15 mTorr -100 C 
Han’s Recipe 70 sccm 4.0 sccm 60W 900W 10mTorr -100 C 
Arif Modified 
Recipe 
90 sccm 30 sccm 30W 900W 15mTorr -100 C 
Table 1: List of etching recipes 
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Width of Trench Si etch rate 
50 um 2.08 um/min 
800 um 8.3 um/min 
Table 2: Etching rate for Akil 45 min etch 
 
Width of Trench Si etch rate 
50 um 2 um/min 
800 um 3 um/min 
Table 3: Etch rate using Oxford recipe 
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Figure 31: Etch rate vs trench width 
 
 The recipes showing the deepest etch down to 150 um were Akil’s 45 minute 
etch, shown in Table 2, and Oxford’s recipe, shown in Table 3. Despite having an 
increased oxygen flow rate, Akil’s 45 minute etch achieved the same etch rate for a 50 
um width trench as Oxford’s recipe due to increased RF power. These recipes achieved 
similar etch depths as well as sidewall profiles. This is interesting due to the difference 
in the ratios between SF6 and O2. In general, as the width of the trench increased, the 
etch rates decreased as shown in Figure 31.  
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CHAPTER IV 
SUMMARY AND FUTURE WORK 
 
4.1 Effect of Recirculation of Aggregates 
 A microfluidic device was successfully designed, fabricated and tested for the 
recirculation of cellular aggregates. This device enables reflow of cellular aggregates 
within a microfluidic platform. The wide ranging implications of such a device include 
the recirculation of neuronal aggregates through aggregate trapping structures. This will 
limit neuronal aggregate loss reducing the cost of myelination studies. This impacts the 
previous research performed on the myelination of neuronal aggregates increasing the 
efficiency of myelination studies. Furthermore, the recirculation design provides the 
potential for a high throughput design. The design will be increased to contain up to 48 
aggregate trapping chambers. An inlet and outlet for each row of aggregate trapping 
chambers will be included along with more mircovalves to control the flow of media 
into and out of the chambers. This will allow parallel testing of different drug 
compounds or different concentrations of drugs within each row of aggregate culturing 
chambers. Continued testing with different cell aggregates will be done including tests 
with neuronal aggregates. Uniform aggregates will be culturing within microwells and 
circulated through the trapping chambers. The fabrication of a recirculation design that 
includes the aggregate trapping pillars is necessary for continued research into the 
trapping efficiency. Incorporation of the trapping pillars into the design is discussed in 
the following section.  
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4.2 Aggregate Traps  
  Fabrication of the aggregate trapping pillars will continue to be tested within 
Texas A&M’s Aggiefab. Increasing the size of the pillars as well as the distance between 
the pillars may help in the fabrication process. Etching of trenches into silicon with the 
tools availbale at Texas A&M has shown the capabilities to etch structures as deep as 
150 um. If the size of the trapping structures is increased significantly then it is possible 
to fabricate the structures using SU-8 photoresist without the detrimental peeling effect. 
If unsuccessful in fabrication of the trapping pillars using currently available techniques, 
the device will be fabricated by a professional DRIE lab.  
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